{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/palliative-care-secretions/prescribing-information/administering-drugs-via-syringe-driver/","result":{"pageContext":{"chapter":{"id":"c4ecff94-72a7-5298-9eff-aa0f014bd0d2","slug":"administering-drugs-via-syringe-driver","fullItemName":"Administering drugs via syringe driver","depth":2,"htmlHeader":"<!-- begin field 46a0b9e7-649a-4574-b74c-e0f1f27ef1e4 --><h2>How do I administer anti-emetic drugs via a syringe driver?</h2><!-- end field 46a0b9e7-649a-4574-b74c-e0f1f27ef1e4 -->","summary":"","htmlStringContent":"<!-- begin item 26c48d37-1fa0-4e31-9347-ef4fdf3ec2ea --><!-- begin field c30f884d-4ac9-45bf-8c16-d3c173a143bd --><ul><li>Drug delivery via syringe drivers is an option if the person cannot take medicines by mouth.</li><li>Only drugs that are known to be safe and effective when administered subcutaneously should be used. Use water for injection as the diluent when mixing drugs in a syringe driver (except for ketamine or octreotide).</li><li>Before mixing drugs, check their compatibility.<ul><li>Always follow local palliative care guidelines or seek advice from local palliative care services or hospital pharmacy drug information services before mixing drugs in a syringe driver.</li><li>Data are most often available on combinations of two drugs in a syringe driver, although some combinations of three or four drugs are compatible.</li><li>The following combinations of three drugs may be <em>incompatible</em>:<ul><li>Cyclizine + haloperidol + hyoscine butylbromide: generally regarded as incompatible.</li><li>Cyclizine + hyoscine butylbromide + midazolam: observational reports of incompatibility.</li><li>Cyclizine 8.82 mg/ml + dexamethasone sodium phosphate 0.71 mg/ml + hyoscine butylbromide 2.35 mg/ml reported compatible: incompatibility may occur at higher doses.</li></ul></li><li>If you cannot contact the appropriate authorities for further guidance, see the <a href=\"http://www.palliativedrugs.com/syringe-driver-database-introduction.html\" data-hyperlink-id=\"8c8cd8af-cf81-491f-a987-a99300287bac\">Syringe Driver Survey Database</a> within the website <a href=\"http://www.palliativedrugs.com/index.html\" data-hyperlink-id=\"521d5148-c7c4-4a6d-8de0-a99300287be4\">palliativedrugs.com</a>. This site requires registration. In addition, Table 3 provides a brief guide to two drug combination compatibilities.</li></ul></li><li><strong>Do not use solutions that are discoloured or have precipitated.</strong></li></ul><p><strong>Table 3.</strong> Compatibility for two drugs commonly given by syringe driver</p><table><thead><tr><th colspan=\"1\">Drug</th><th colspan=\"1\">Hyoscine butylbromide</th><th colspan=\"1\">Hyoscine hydrobromide</th><th colspan=\"1\">Glycopyrronium bromide</th></tr></thead><tbody><tr><td colspan=\"1\">Alternative routes of administration of the named drug or different drug option</td><td colspan=\"1\">Hyoscine butylbromide as a subcutaneous injection every 4–6 hours</td><td colspan=\"1\">Hyoscine hydrobromide sublingual tablets or transdermal patches</td><td colspan=\"1\">Hyoscine hydrobromide sublingual tablets transdermal or patches</td></tr><tr><td colspan=\"1\" rowspan=\"9\">Reported compatability</td><td colspan=\"1\">Alfentanil</td><td colspan=\"1\">Clonazepam</td><td colspan=\"1\">Alfentanil</td></tr><tr><td colspan=\"1\">Clonazepam</td><td colspan=\"1\">Cyclizine</td><td colspan=\"1\">Clonazepam</td></tr><tr><td colspan=\"1\">Diamorphine</td><td colspan=\"1\">Diamorphine</td><td colspan=\"1\">Diamorphine</td></tr><tr><td colspan=\"1\">Haloperidol</td><td colspan=\"1\">Haloperidol</td><td colspan=\"1\">Levomepromazine</td></tr><tr><td colspan=\"1\">Levomepromazine</td><td colspan=\"1\">Levomepromazine</td><td colspan=\"1\">Metoclopramide*</td></tr><tr><td colspan=\"1\">Midazolam</td><td colspan=\"1\">Midazolam</td><td colspan=\"1\">Midazolam</td></tr><tr><td colspan=\"1\">Morphine sulphate</td><td colspan=\"1\">Morphine sulphate</td><td colspan=\"1\">Morphine sulphate</td></tr><tr><td colspan=\"1\">Octreotide</td><td colspan=\"1\">Oxycodone*</td><td colspan=\"1\">Oxycodone†</td></tr><tr><td colspan=\"1\">Oxycodone*</td><td colspan=\"1\"> </td><td colspan=\"1\"> </td></tr><tr><td colspan=\"1\" rowspan=\"4\">Incompatible</td><td colspan=\"1\">Diclofenac</td><td colspan=\"1\">Diclofenac</td><td colspan=\"1\">Dexamethasone</td></tr><tr><td colspan=\"1\">Furosemide</td><td colspan=\"1\">Furosemide</td><td colspan=\"1\">Diclofenac</td></tr><tr><td colspan=\"1\"> </td><td colspan=\"1\"> </td><td colspan=\"1\">Furosemide</td></tr><tr><td colspan=\"1\"> </td><td colspan=\"1\"> </td><td colspan=\"1\">Ketorolac</td></tr><tr><td colspan=\"1\" rowspan=\"3\">Use with caution. Compatibility may depend on order or mixing of drug concentrations</td><td colspan=\"1\">Dexamethasone</td><td colspan=\"1\">Dexamethasone</td><td colspan=\"1\">—</td></tr><tr><td colspan=\"1\">Cyclizine</td><td colspan=\"1\">Also metoclopramide is not generally recommended</td><td colspan=\"1\"> </td></tr><tr><td colspan=\"1\">Also metoclopramide is not generally recommended</td><td colspan=\"1\"> </td><td colspan=\"1\"> </td></tr><tr><td colspan=\"1\" rowspan=\"6\">No data</td><td colspan=\"1\">Hydromorphone</td><td colspan=\"1\">Alfentanil</td><td colspan=\"1\">Cyclizine</td></tr><tr><td colspan=\"1\">Ketamine</td><td colspan=\"1\">Hydromorphone</td><td colspan=\"1\">Haloperidol</td></tr><tr><td colspan=\"1\">Ketorolac</td><td colspan=\"1\">Ketamine</td><td colspan=\"1\">Hydromorphone</td></tr><tr><td colspan=\"1\">Ondansetron</td><td colspan=\"1\">Ketorolac</td><td colspan=\"1\">Ketamine</td></tr><tr><td colspan=\"1\"> </td><td colspan=\"1\">Ondansetron</td><td colspan=\"1\">Octreotide</td></tr><tr><td colspan=\"1\"> </td><td colspan=\"1\"> </td><td colspan=\"1\">Ondansetron</td></tr><tr><td colspan=\"4\">*Although compatible, the action of metoclopromide may be antagonized by an antimuscarinic drug such as glycopyrronium bromide [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-secretions/references/\">BNF 72, 2016</a>]. <sup>†</sup>Some differences in compatability have been demonstrated for the 10 mg/mL and the 50 mg/mL formulations of oxycodone solution for injection. It is important to check compatability information for each formulation</td></tr><tr><td colspan=\"4\"><strong>Data from: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-secretions/references/\">Regnard, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-secretions/references/\">Twycross, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-secretions/references/\">Wilcock, Personal Communication, 2012</a>]</td></tr></tbody></table><p>These recommendations are based on expert opinion in a palliative care textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-secretions/references/\">Regnard, 2010</a>], the Palliative Care Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-secretions/references/\">Twycross, 2014</a>], and the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-secretions/references/\">BNF 72, 2016</a>].</p><!-- end field c30f884d-4ac9-45bf-8c16-d3c173a143bd --><!-- end item 26c48d37-1fa0-4e31-9347-ef4fdf3ec2ea -->","topic":{"id":"77f1b9af-1e60-5bb5-ae89-daa331210abe","topicId":"446cb057-c3b6-49c3-942c-3d8a40d02345","topicName":"Palliative care - secretions","slug":"palliative-care-secretions","lastRevised":"Last revised in October 2016","chapters":[{"id":"19f54d42-0888-50d9-a22b-cd4c095d346e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"72433d6d-9301-5ca8-b910-6a552d6fce9c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"025bff54-f52a-54fb-b384-42f6b7abfb71","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"09dcf8ce-9483-5303-b1b2-68579072438f","slug":"changes","fullItemName":"Changes"},{"id":"fffc9f9e-45d1-50c5-be5f-b864988702ac","slug":"update","fullItemName":"Update"}]},{"id":"f0f7d1a1-4f58-53b4-a82a-1cee73e34be5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5cf603f8-c6db-5f9a-8053-8078d5ca7704","slug":"goals","fullItemName":"Goals"},{"id":"d5a9411c-4efe-55f8-a100-b669fa635333","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6a870297-6340-5e00-91f5-76791ba8bc25","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"acfb93e5-0ab7-5b5e-abea-421e101ee036","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"76d1d9b7-098a-51c5-a8c8-ed432c562045","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"82517897-fd42-5e8b-9c87-986916cd1a05","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d4296b2d-b51d-58ce-8564-c1f97f3e17d1","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7f6c0c77-0b74-5509-99a0-d46ccbb5df6a","slug":"definition","fullItemName":"Definition"},{"id":"a280c209-3fa8-5a6e-8cf1-77ecdb0c548f","slug":"why-do-secretions-accumulate","fullItemName":"Why do secretions accumulate"},{"id":"fcc81d76-7a24-5377-9a9c-871e7849434d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"6b5cc8f0-3cab-5d14-900a-459f40793235","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"aeac360c-7bd9-5b2d-a7f0-979347e4a423","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b6e50011-ccf0-5fd1-b5ba-a11dab328604","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"6f40bc41-9977-54ec-b25f-77e34d1c3cac","fullItemName":"Management","slug":"management","subChapters":[{"id":"1365445e-f6e4-583d-84ac-dfa2d7ec2981","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"f01d488f-b942-5c1f-839b-84f60cb644a3","slug":"noisy-respiratory-secretions-at-the-end-of-life","fullItemName":"Scenario: Noisy respiratory secretions at the end of life"}]},{"id":"8d463ab9-510c-50ff-b9e2-2a5202e4693e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"24d654c1-72b5-5691-b5ab-2b633207259e","slug":"which-antimuscarinic-to-prescribe","fullItemName":"Which antimuscarinic to prescribe"},{"id":"1819f9d9-cb20-5283-9237-36370d8eaf04","slug":"dose-of-antimuscarinic","fullItemName":"Dose of antimuscarinic"},{"id":"0e997e9e-35ef-5150-9b22-44631bbe9875","slug":"adverse-effects-of-antimuscarinics","fullItemName":"Adverse effects of antimuscarinics"},{"id":"c4ecff94-72a7-5298-9eff-aa0f014bd0d2","slug":"administering-drugs-via-syringe-driver","fullItemName":"Administering drugs via syringe driver"}]},{"id":"fc7ec3a1-6164-5fce-ae68-ea76a7e7ed95","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[{"id":"f0bd35d1-28aa-5304-bbae-6437a5cff4f8","slug":"antimuscarinics-for-respiratory-secretions","fullItemName":"Antimuscarinics for respiratory secretions"}]},{"id":"13aa02e3-ed7e-5603-b3cf-c8c77f16c1ad","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9720e3b4-46d0-5fc7-a0db-be67e6db6bfa","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"92414bd0-2c9f-584a-badf-10b45f202fc3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"42fc232e-bba3-513f-a5d9-15378200e570","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"68c17f61-0db1-544c-a0b5-b14bb9ce5c5c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"bf6037b2-67c3-5d11-ae91-c606813ad76d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"741bbef8-7d2e-53e4-ae09-0cb22ef8d617","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"8d463ab9-510c-50ff-b9e2-2a5202e4693e","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}